Perioperative antimicrobial prophylaxis in clean-contaminated head and neck squamous cell cancer surgeries: Is less better?

被引:1
|
作者
Kohli, Pavneet [1 ]
Penumadu, Prasanth [1 ]
Shukkur, Naveeth [1 ]
Sivasanker, M. [3 ]
Balasubramanian, Arumugam [1 ]
Ganapathy, Sachit [2 ]
机构
[1] JIPMER, Dept Surg Oncol, Pondicherry, India
[2] JIPMER, Dept Biostat, Pondicherry, India
[3] Royal Liverpool Univ Hosp NHS Trust, Dept Surg, Liverpool, Merseyside, England
关键词
Antibiotic misuse; antibiotic resistance; clean-contaminated surgery; head and neck surgery; oral cancer; SSI; SURGICAL SITE INFECTIONS; ANTIBIOTIC-PROPHYLAXIS; ONCOLOGIC SURGERY; SHORT-TERM; COMPLICATIONS; PREVENTION; CLASSIFICATION; METRONIDAZOLE; CLINDAMYCIN; CEFAZOLIN;
D O I
10.4103/jcrt.JCRT_1654_20
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Judicious use of antibiotics and stringent adherence to practice guidelines is the need of the hour as antibiotic resistance is a rampant problem. Despite several reports in the literature describing the optimal duration of antibiotics, there is no consensus. A "one for all" protocol may be impractical and hence the guidelines need to be tweaked to take into consideration local factors. We designed a protocol for prophylactic antibiotics in clean-contaminated head and neck cancer squamous cell carcinoma (HNSCC) surgeries to prevent unchecked abuse and evaluated its feasibility. Materials and Methods: Two hundred consecutive patients who underwent a clean-contaminated surgery for HNSCC between January 2017 and December 2019 were included. Single-dose intravenous amoxicillin-clavulanate at induction followed by three doses of amoxicillin-clavulanate, metronidazole, and amikacin in the postoperative period was used. Adherence to the antibiotic protocol was assessed from a prospectively maintained database. Results: The mean age was 55.99 +/- 11.71 years. The protocol was effective in 70% of the patients with an acceptable surgical site infection (SSI) rate of 12%. Flap-related complications (9.5%) and oro-cutaneous fistula (5%) were common causes of prolonged antibiotics. On univariate analysis, blood transfusion (P =.014), clinical stage at presentation (P =.028), patients undergoing reconstruction (P =.001), longer operative time (P =.009), and pathological T stage (P = 0.03) were at higher chance of deviating from the protocol. On multivariate analysis, age more than 50 years (OR: 2.14, 95% CI: (1.01, 4.52); P value = 0.047) and reconstruction (OR: 3.36, 95% CI: (1.21, 9.32); P value = 0.020) were found to be significant. Conclusions: A three-dose perioperative antibiotic prophylaxis in clean-contaminated HNSCC surgeries is feasible. Similar protocols should be developed and validated at other major centers to limit the unnecessary use of antibiotics and prevent the emergence of antibiotic resistance.
引用
收藏
页码:S170 / S176
页数:7
相关论文
共 50 条
  • [41] Nivolumab for Squamous-Cell Cancer of Head and Neck
    Gonzalez-Rodriguez, Elisa
    Rodriguez-Abreu, Delvys
    Boronat, Mauro
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (06): : 595 - 595
  • [42] Head and neck squamous cell cancer: Biology (1)
    Mishra A.
    Pandey A.
    Nong X.
    Indian Journal of Otolaryngology and Head & Neck Surgery, 2007, 59 (1) : 28 - 32
  • [43] CHEMOTHERAPY OF SQUAMOUS-CELL CANCER OF THE HEAD AND NECK
    GILL, PG
    HAINS, JD
    IYER, P
    ROZENBILDS, JG
    AHMAD, A
    ABBOTT, RL
    DAVID, DJ
    WARD, GG
    BROWN, MW
    DEANE, N
    HARVEY, M
    MEDICAL JOURNAL OF AUSTRALIA, 1983, 1 (10) : 463 - 466
  • [44] Current Treatment of Head and Neck Squamous Cell Cancer
    Belcher, Ryan
    Hayes, Katherine
    Fedewa, Stacey
    Chen, Amy Y.
    JOURNAL OF SURGICAL ONCOLOGY, 2014, 110 (05) : 551 - 574
  • [45] PRECISION MEDICINE FOR SQUAMOUS CELL CANCER OF THE HEAD AND NECK
    Harrington, Kevin J.
    ACTA DERMATO-VENEREOLOGICA, 2020, 100 : 7 - 8
  • [46] Pembrolizumab for the treatment of head and neck squamous cell cancer
    Ho, Won Jin
    Mehra, Ranee
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (09) : 879 - 885
  • [47] Development on squamous-cell cancer of the head and neck
    Garcia Saenz, J. A.
    Bueno Muino, C.
    ANALES DE MEDICINA INTERNA, 2008, 25 (04) : 157 - 158
  • [48] EPIDEMIOLOGY OF SQUAMOUS-CELL CANCER OF THE HEAD AND NECK
    CANN, CI
    FRIED, MP
    ROTHMAN, KJ
    OTOLARYNGOLOGIC CLINICS OF NORTH AMERICA, 1985, 18 (03) : 367 - 388
  • [49] Prognosis in recurrent head and neck squamous cell cancer
    Baatenburg de Jong, R. J.
    Steyerberg, E.
    van der Schroeff, M.
    ORAL ONCOLOGY, 2007, : 58 - 58
  • [50] Systemic chemotherapy for squamous cell head and neck cancer
    Adelstein, DJ
    EXPERT OPINION ON PHARMACOTHERAPY, 2003, 4 (12) : 2151 - 2163